SCHEMBL26045155

SCHEMBL26045155

N=Cc1cc(Br)c(Nc2ccc(F)cc2)cc1N

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
PRKD3 O94806 1/20 0.36
EGFR P00533 1/20 0.36
PRKCG P05129 1/20 0.36
PRKCB P05771 1/20 0.36
SRC P12931 1/20 0.36
PRKCA P17252 1/20 0.36
PRKCH P24723 1/20 0.36
PRKCI P41743 1/20 0.36
PRKCE Q02156 1/20 0.36
PRKCQ Q04759 1/20 0.36
PRKCZ Q05513 1/20 0.36
PRKCD Q05655 1/20 0.36
PRKD1 Q15139 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SOS1 Q07889 2/20 0.35
KCNH2 Q12809 2/20 0.33
SCN5A Q14524 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23904233 0.95 MAPT (0.36) MAPTMEN1KMT2APRKD3EGFR
SCHEMBL25794401 0.77 KMT2A (0.36) MAPTMEN1KMT2APRKD3EGFR
SCHEMBL25804586 0.74 ACP1 (0.38) MAPTMEN1KMT2APRKD3EGFR
SCHEMBL21901147 0.74 MEN1 (0.30) MAPTMEN1KMT2APRKD3EGFR
SCHEMBL20036833 0.74 MAPT (0.41) MAPTMEN1KMT2APRKD3EGFR
SCHEMBL22828956 0.74 TDP1 (0.40) MAPTMEN1KMT2APRKD3EGFR
SCHEMBL26495850 0.74 MAPT (0.41) MAPTMEN1KMT2APRKD3EGFR
SCHEMBL24283166 0.72 MAPK10 (0.37) MAPTMEN1KMT2APRKD3EGFR
SCHEMBL14549154 0.70 KDM1A (0.32) KCNH2
SCHEMBL21900949 0.69 HDAC1 (0.34) MAPK10MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265080-A1 MODULATORS OF ALPHA-1 ANTITRYPSIN VERTEX PHARMA (US) 2023-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265080-A1 MODULATORS OF ALPHA-1 ANTITRYPSIN SERPINA2, SERPINA3, SERPINB1 MAPT 1912/4885MEN1 1921/4885KMT2A 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.